Skip to main content

Ernesto Trallero Araguas

Institutions of which they are part

Main researcher
Rheumatology
Vall Hebron Institut de Recerca

Ernesto Trallero Araguas

Institutions of which they are part

Main researcher
Rheumatology
Vall Hebron Institut de Recerca

Projects

Caracterización de las células patogénicas del músculo y piel de pacientes con Dermatomiositis y Síndrome Antisintetasa y estudio de aplicabilidad traslacional

IP: Ernesto Trallero Araguas
Collaborators: Miriam Izquierdo Sans
Funding agency: Fundación Española de Reumatología
Funding: 30000
Reference: FER/TRALLERO/2023
Duration: 21/10/2023 - 20/10/2024

Caracterización de las células patogénicas del músculo y piel de pacientes con Dermatomiositis y Síndrome Antisintetasa y estudio de aplicabilidad traslacional.

IP: Ernesto Trallero Araguas
Collaborators: Albert Selva O'Callaghan, Raul Tortosa Mendez, Albert Gil Vila, Gloria Aparicio Español, Caracterización de las células patogénicas del músculo y piel de pacientes con Dermatomiositis y Síndrome Antisintetasa y estudi, Hugo Fernando Avalos Bogado
Funding agency: Instituto de Salud Carlos III
Funding: 135520
Reference: PI22/00708
Duration: 01/01/2023 - 31/12/2025

Inflitrado tumoral linfocitario (TIL) y dematomiositis asociada a cáncer.

IP: Albert Selva O'Callaghan
Collaborators: Ernesto Trallero Araguas, Maria Eugenia Semidey Raven
Funding agency: Instituto de Salud Carlos III
Funding: 129470
Reference: PI18/01609
Duration: 01/01/2019 - 30/06/2023

Identificación de nuevos antígenos en pacientes con miopatía inflamatoria

IP: Albert Selva O'Callaghan
Collaborators: Ernesto Trallero Araguas
Funding agency: Instituto de Salud Carlos III
Funding: 121000
Reference: PI15/02100
Duration: 01/01/2016 - 30/11/2020

Related news

The new therapeutic strategy aims at maintaining the efficacy of thalidomide while avoiding its main systemic adverse effects.

The event, held as part of World Lupus Day, incorporated the perspective of people living with the disease to address the challenges associated with lupus.

The global biopharmaceutical company UCB has acquired the data and clinical knowledge business of IMIDomics, a spin-off of the Vall d’Hebron Institute of Research (VHIR).

Related professionals

Santi Biel Boatas

Santi Biel Boatas

Predoctoral researcher
Psychiatry, Mental Health and Addictions
Read more
Laura Rodriguez Garcia

Laura Rodriguez Garcia

Research assistant
Pneumology
Read more
Marina Viñas Jornet

Marina Viñas Jornet

Senior researcher
Genetics Medicine
Read more
Guillem Puigsech Boixeda

Guillem Puigsech Boixeda

Predoctoral researcher
Microbiology
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.